Adriamycin in Adults with Neoplastic Diseases

  • Irwin H. Krakoff
Conference paper

Abstract

It is perhaps inappropriate for my report to follow that of Dr. Bonadonna who has had by far the most extensive experience with adriamycin and whose experience has been substantially better than we have seen.

Keywords

Toxicity Depression Lymphoma Leukemia Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arcamone, F., Franceschi, G., Tneco, S., Selva, A.: Tetrahedron Letters 13,1007–1010 (1969).PubMedCrossRefGoogle Scholar
  2. 2.
    Di Marco, A., Gaetani, M., Scarpinato, B.: Cancer Chem. Rept. 53, 33–37 (1969).Google Scholar
  3. 3.
    Bonadonna, G., Monfardini, S., De Lena, M., Fossati-Bellani, F.: Brit. med. J. 1969 III, 503–506.Google Scholar
  4. 4.
    Bonadonna, G., Monfardini, S., De Lena, M., Fossati-Bellani, F., Beretta, G.: Cancer Res. 30, 2572 (1970).PubMedGoogle Scholar
  5. 5.
    Karnofsky, D. A., Burchenal, J. H.: The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod, C. M. (Ed.): Evaluation of Chemotherapeutic Agents. New York: Columbia University Press 1949.Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1972

Authors and Affiliations

  • Irwin H. Krakoff
    • 1
    • 2
  1. 1.Medical Oncology Service, Department of MedicineMemorial Hospital for Cancer and Allied diseasesUSA
  2. 2.Division of Chemotherapy ResearchSloan-Kettering Institute for Cancer ResearchNew YorkUSA

Personalised recommendations